Drägerwerk AG & Co. KGaA (ETR:DRW3) outlined its current positioning and financial priorities during a presentation at a German Select Conference, with Head of Treasury and Investor Relations Thomas Fischler highlighting the company’s two-division structure, recent earnings momentum, and growth opportunities in hospital interoperability and defense-related safety equipment.
Fischler said Dräger’s business is anchored in its “Technology for Life” philosophy, describing the company’s portfolio as focused on products that “protect, support, and save lives.” He noted the group operates in two divisions—Medical and Safety—with an approximate 60/40 split in net sales.
→ 3 Surprising S&P 500 Outperformers of 2026
Geographically, Fischler said around 20% of net sales are generated in Germany, with Europe and the Middle East representing about 40%. The Americas account for a significant portion as well, including roughly $450 million of net sales in the U.S., while Asia Pacific is the smallest reporting region at 16%.
He added that about 60% of employees are customer-facing, with roughly 20% in production, quality, and logistics, and about 10% each in R&D and administration. Dräger sells in “basically every country,” he said, with its own subsidiaries in about 50 countries. Production and development sites are concentrated in a smaller number of locations, including Lübeck as the largest, a U.S. facility for patient monitoring, SCBA manufacturing in the U.K., and China operations designed to serve local-content requirements. Fischler said the company is also building a new facility in India intended to develop and produce products for that fast-growing market and similar markets in the region.
→ Microsoft’s Copilot Problem Isn’t What You Think
Within the Medical division, Fischler said Dräger targets high-acuity areas of hospitals such as operating rooms and intensive care units, rather than lower-acuity wards. He identified anesthesia and ventilation as the largest franchises by sales and earnings, followed by workplace infrastructure products and thermoregulation (including incubators). Aftersales—services and consumables—accounts for roughly “40 and above percent” of Medical division net sales depending on the year, he said.
Patient monitoring is a smaller business where Dräger is “a market follower,” Fischler said, but he called it strategically important as the company shifts innovation toward interoperability across devices. He argued core devices like anesthesia machines and ventilators are mature and increasingly commoditized, making connectivity and integrated workflows an important future differentiator.
